As­traZeneca and Chi­na part­ner Chi-Med launch a glob­al PhI­II; Zai Lab bags $30M for R&D ef­fort

→ Un­der­scor­ing a com­mit­ment to de­vel­op­ing can­cer drugs for a world mar­ket, Chi­na’s Chi-Med and its part­ners at As­traZeneca have start­ed a Phase III for savoli­tinib in c-MET-dri­ven pap­il­lary re­nal cell car­ci­no­ma. The move trig­gers a $5 mil­lion mile­stone pay­ment un­der their pact and marks a move to­ward US and Eu­ro­pean mar­ket­ing ap­pli­ca­tions, if all goes ac­cord­ing to plan.

→ Shang­hai-based Zai Lab has round­ed up a $30 mil­lion C round for its R&D work with an eye to fu­ture part­ner­ing deals.  Or­biMed led this round of fi­nanc­ing with oth­er new in­vestors Vi­vo Cap­i­tal, Cor­morant and Rock Springs Cap­i­tal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER